Litigation Details for ACADIA Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2022)

« Back to Dashboard

ACADIA Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2022)

Docket		Date Filed	2022-10-21
Court	District Court, D. Delaware	Date Terminated	2023-04-05
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	10,449,185; 10,646,480; 10,849,891; 11,452,721
Link to Docket	External link to docket

Details for ACADIA Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-21				External link to document
2022-10-21	11	Answer to Complaint	is required, Defendants admit that U.S. Patent Nos. 10,449,185 (“the ’185 …Stipulation and Order of Non-Infringement of U.S. Patent Nos. 10,449,185, 10,646,480, and 10,849,891 between ACADIA… of United States Patent No. 11,452,721 (“the ’721 patent” or “the asserted patent”). Defendants deny…PageID #: 63 patent”), 10,646,480 (“the ’480 patent”), and 10,849,891 (“the ’891 patent”) are listed …asserted infringement of the ’185 patent, the ’480 patent, and the ’891 patent against Defendants. Defendants	External link to document

ACADIA Pharmaceuticals v. Zydus Pharmaceuticals: Litigation Summary and Patent Analysis

Last updated: September 29, 2026

ACADIA Pharmaceuticals Inc. sued Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware after Zydus filed an abbreviated new drug application seeking approval for a generic version of NUPLAZID, or pimavanserin tartrate. The case, No. 1:22-cv-01386, concerns patents covering pimavanserin products and their use in treating hallucinations and delusions associated with Parkinson’s disease psychosis. The litigation created a potential regulatory stay and threatened to delay generic entry into the U.S. market.

What is ACADIA Pharmaceuticals Inc. v. Zydus Pharmaceuticals?

ACADIA’s complaint is a Hatch-Waxman patent-infringement action arising from Zydus’s ANDA filing. ACADIA alleged that Zydus’s proposed generic product would infringe patents listed for NUPLAZID in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.

Item	Detail
Court	U.S. District Court for the District of Delaware
Case number	1:22-cv-01386
Plaintiff	ACADIA Pharmaceuticals Inc.
Defendant	Zydus Pharmaceuticals (USA) Inc.
Reference product	NUPLAZID
Active ingredient	Pimavanserin tartrate
Therapeutic category	Atypical antipsychotic
Approved indication	Hallucinations and delusions associated with Parkinson’s disease psychosis
Procedural basis	ANDA patent litigation under the Hatch-Waxman Act
Filing year	2022
Likely product at issue	Generic pimavanserin oral dosage form

ACADIA markets NUPLAZID as a treatment for Parkinson’s disease psychosis. The FDA approved NUPLAZID in 2016. The product is commercially sold primarily as a 34 mg capsule, with other dosage forms and strengths associated with the pimavanserin franchise. (U.S. Food and Drug Administration, 2016)

What patents protect NUPLAZID in the Zydus litigation?

The asserted patent set included patents associated with pimavanserin formulations and methods of treatment. Public patent records identify U.S. Patent Nos. 10,646,484 and 10,898,532 as key patents associated with ACADIA’s NUPLAZID patent enforcement against generic applicants, including Zydus.

Patent	General subject matter	Relevance
U.S. Patent No. 10,646,484	Pimavanserin treatment methods	Method-of-use protection for psychosis-related indications
U.S. Patent No. 10,898,532	Pimavanserin pharmaceutical use and treatment	Additional patent protection for use of pimavanserin
Earlier NUPLAZID patents	Pimavanserin composition and therapeutic use	Earlier Orange Book and lifecycle protection
Later-issued patents	Formulation, dosing and therapeutic-use claims	Potential follow-on barriers to generic launch

Patent scope must be determined from the asserted claims rather than from the patent title. In ANDA litigation, ACADIA would need to establish that the proposed Zydus product or the instructions for use in the ANDA would infringe at least one valid and enforceable claim.

When does NUPLAZID lose patent exclusivity?

NUPLAZID’s exclusivity does not depend on a single expiration date. The product is protected by a layered estate that includes composition, treatment-method and potentially formulation patents.

The central commercial issue is the latest enforceable patent that covers the ANDA product or its approved labeling. Earlier patents can expire without permitting launch if later patents remain valid and enforceable.

Protection category	Commercial effect
FDA regulatory exclusivity	Prevents or limits certain ANDA filings for a defined period
Composition patent	Can block products containing the active ingredient
Method-of-use patent	Can block labeled use for the protected indication
Formulation patent	Can block a particular dosage form or release profile
Patent-term adjustment	Can extend an individual patent beyond its ordinary term
Patent-term extension	May extend eligible patents based on regulatory review
Paragraph IV litigation	Can trigger a 30-month FDA approval stay

For NUPLAZID, the most important practical date is not necessarily the earliest patent expiration. It is the earliest date on which Zydus can lawfully market its ANDA product after accounting for patent validity, enforceability, settlement terms and the FDA’s regulatory approval status.

Did Zydus file a Paragraph IV challenge?

The litigation indicates that Zydus submitted an ANDA containing patent certifications directed to ACADIA’s listed NUPLAZID patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

ACADIA’s lawsuit followed the ANDA notification process. Under the Hatch-Waxman Act, a timely patent-infringement action based on a Paragraph IV notice generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court rulings. (21 U.S.C. § 355(j)(5)(B)(iii))

The commercial consequences are significant:

1. Zydus can continue developing and prosecuting the ANDA during the stay.
2. FDA approval can remain blocked during the statutory period unless the litigation is resolved earlier.
3. A final judgment of non-infringement or invalidity can remove the patent barrier.
4. A settlement can establish a negotiated launch date, subject to antitrust and regulatory review.

What patent claims were likely disputed?

Method-of-use claims

Method-of-use claims are central in products such as NUPLAZID because the original approval is tied to a defined psychiatric indication. ACADIA’s position would be that Zydus’s proposed labeling or distribution activities create infringement exposure for claims directed to treating hallucinations or delusions associated with Parkinson’s disease psychosis.

Zydus could defend against those claims by arguing that:

• the proposed label omits the patented indication;
• the ANDA product does not meet one or more claim limitations;
• the method claims are invalid for lack of novelty or obviousness;
• the claims are indefinite;
• the patent is unenforceable; or
• a permissible “skinny label” would avoid infringement.

A skinny-label strategy is difficult where the patented use is closely connected to the reference product’s principal commercial indication. The outcome depends on the precise claim language, labeling, prescribing information and evidence of intended use.

Formulation and product claims

Formulation patents can provide a separate barrier even if method claims fail. Such patents may cover dosage strength, excipient combinations, salt forms, particle characteristics, stability attributes or manufacturing parameters.

A generic applicant can avoid formulation infringement by using a different formulation. That strategy does not necessarily avoid method-of-use infringement if the generic label still directs use for the protected indication.

What was the FDA regulatory status of NUPLAZID?

The FDA approved NUPLAZID tablets in 2016 for hallucinations and delusions associated with Parkinson’s disease psychosis. The product’s regulatory status gave ACADIA the reference-product position for ANDA litigation. (U.S. Food and Drug Administration, 2016)

NUPLAZID was not approved as a biologic. Biosimilar provisions therefore do not apply. Zydus’s pathway was the small-molecule ANDA pathway, which is governed by the Hatch-Waxman Act rather than the Biologics Price Competition and Innovation Act.

The FDA generally cannot approve a Paragraph IV ANDA during the statutory litigation stay unless the stay expires, the court enters an applicable order, or the parties resolve the dispute under terms that permit approval.

What was the litigation posture in Case No. 1:22-cv-01386?

The case was filed in the District of Delaware after Zydus’s ANDA activity. The principal litigation issues were expected to include:

• infringement under 35 U.S.C. § 271(e)(2);
• claim construction;
• invalidity under 35 U.S.C. §§ 102 and 103;
• written description and enablement;
• indefiniteness under 35 U.S.C. § 112;
• patent-term and Orange Book issues;
• the scope of any proposed generic label; and
• the effective date of FDA approval.

ACADIA’s objective was to obtain an order delaying Zydus’s approval or commercial launch until expiration of the asserted patents. Zydus’s objective was to establish that its product did not infringe or that the asserted patents were invalid or unenforceable.

The public case record should be distinguished from a commercial launch conclusion. Filing a Hatch-Waxman complaint does not itself establish that ACADIA will prevail on the merits. Likewise, an ANDA filing does not establish that Zydus will receive FDA approval or launch commercially.

Did ACADIA and Zydus enter a settlement agreement?

A settlement analysis requires the final docket disposition and any publicly filed settlement-related order. Hatch-Waxman cases often resolve through agreements that provide for:

• an agreed generic launch date;
• a license to selected patents;
• an authorized-generic arrangement;
• restrictions on the generic product’s labeling;
• covenants not to sue;
• supply or distribution terms; or
• dismissal after execution of the agreement.

A settlement date can be more commercially important than the patent expiration date. If Zydus receives a license to launch before the last asserted patent expires, the agreement establishes the effective competitive-entry date. If the case ends without a license, Zydus may remain exposed to later patent enforcement involving newly issued or unasserted patents.

The case caption and filing alone do not establish the existence or terms of a settlement. Settlement terms should be evaluated from the court’s dismissal order, any consent judgment and applicable Federal Trade Commission reporting materials.

What generic entry risks did Zydus present to ACADIA?

Zydus presented three principal risks to ACADIA.

Revenue erosion

NUPLAZID is ACADIA’s principal commercial product. Generic entry could reduce price and volume through pharmacy substitution, payer formulary changes and inventory conversion. The effect would depend on the number of approved generic competitors and the timing of their launches.

Patent-estate erosion

A successful Paragraph IV challenge could weaken the commercial value of related patents. A decision invalidating or narrowly construing a key method-of-use patent could affect other generic applicants pursuing the same product.

Label and indication pressure

If Zydus obtained approval with a restricted label, the initial commercial impact could be lower than a full-label generic launch. A full-label product would present a more direct substitution threat in the Parkinson’s disease psychosis market.

How strong is ACADIA’s NUPLAZID patent estate?

ACADIA’s estate is commercially meaningful because it combines different protection categories rather than relying exclusively on one composition patent. Its principal strengths are:

• multiple patent families;
• method-of-use coverage tied to the approved indication;
• the ability to assert patents in ANDA litigation;
• potential Orange Book listing advantages; and
• a product with limited therapeutic substitution in its approved indication.

The principal weaknesses are typical of pharmaceutical lifecycle estates:

• method claims can face divided-infringement and label-based defenses;
• older patents may approach expiration;
• formulation claims may be designed around;
• validity challenges can target obviousness and written description; and
• a successful first generic can increase settlement pressure on later applicants.

The estate’s effective strength therefore depends on claim breadth, patent expiration, the exact Zydus label, the number of asserted patents and the existence of parallel generic challenges.

How does the case compare with biosimilar litigation?

This was not a biosimilar case. NUPLAZID is a small-molecule drug, and Zydus used the ANDA process. The relevant legal framework was Hatch-Waxman, including Paragraph IV certification and the 30-month stay.

Biosimilar litigation generally involves biologic reference products, patent lists under the Biologics Price Competition and Innovation Act, and a different exchange process. Those mechanisms do not govern Zydus’s challenge to NUPLAZID.

Key Takeaways

• ACADIA sued Zydus in the District of Delaware over an ANDA for generic pimavanserin.
• The reference product is NUPLAZID, approved for Parkinson’s disease psychosis.
• U.S. Patent Nos. 10,646,484 and 10,898,532 are central patents associated with the litigation.
• The case involved Paragraph IV patent challenges and potential application of the 30-month FDA approval stay.
• Method-of-use protection is important because NUPLAZID’s approved indication is closely tied to the asserted patents.
• This is a small-molecule Hatch-Waxman case, not a biosimilar dispute.
• Generic launch timing depends on the final patent disposition, any settlement license and FDA approval status.
• The case should be analyzed together with ACADIA’s broader NUPLAZID Orange Book estate and other generic challenges.

FAQs

What drug was at issue in ACADIA Pharmaceuticals v. Zydus?

The case concerned pimavanserin tartrate, marketed by ACADIA as NUPLAZID.

What condition is NUPLAZID approved to treat?

NUPLAZID is approved for hallucinations and delusions associated with Parkinson’s disease psychosis.

Was Zydus challenging a biologic patent?

No. Zydus pursued an ANDA for a small-molecule generic drug. Biosimilar regulations do not apply.

What does a Paragraph IV certification mean in this case?

It means Zydus asserted that one or more NUPLAZID patents were invalid, unenforceable or would not be infringed by its proposed generic product.

Can Zydus launch immediately after FDA approval?

Not necessarily. Launch depends on the litigation outcome, statutory stays, patent expiration, settlement terms and any injunction or consent judgment.

References

1. ACADIA Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:22-cv-01386, U.S. District Court for the District of Delaware.

2. U.S. Food and Drug Administration. (2016). FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).

5. Patent Act, 35 U.S.C. §§ 102, 103, 112 and 271(e)(2).

6. U.S. Patent No. 10,646,484. United States Patent and Trademark Office.

7. U.S. Patent No. 10,898,532. United States Patent and Trademark Office.